

FDA says natural thyroid is a biologic and pharmacies can no longer compound it.

That's not right.

Starting August 2026, DTE can no longer be compounded or dispensed unless FDA reverses its decision.

Help us do something about it.

Congress must push back against this unnecessary overreach by FDA so that patients are not collateral damage in a policy change that in effect clears the field to create a monopoly for one drugmaker.



Tell Congress to:

- ⊖ Keep DTE regulated as a small-molecule drug, consistent with science and decades of precedent.
- ⊖ Reject a monopoly-driven reclassification that limits treatment options and drives up prices for patients.
- ⊖ Protect patient/provider decision-making by preserving access to DTE alongside synthetic alternatives.

The implications are serious for patients who rely on that therapy.

Send a message to FDA

